Abstract: Disclosed are a bridged nucleoside and a nucleotide using the same. The nucleoside of the present invention is represented by the formula (I) below. The bridged nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The bridged nucleoside also has excellent industrial productivity.

Abstract: A discharge electrode E in an electrode chamber C comprises a plurality of electrode members 8, 9. The electrode members 8, 9 are disposed facing each other by having a supporting member 4 therebetween, a gap is formed between the facing portions of the electrode members 8, 9, and by having the gap as a gas passageway 15, the gas passageway is opened in the leading end of the discharge electrode. A replacement gas having been supplied from a manifold pipe 3 is supplied to the gas passageway 15 via an orifice.

Abstract: A medicament comprising a combination of a compound represented by formula (I), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these and an immune checkpoint inhibitor (such as an anti-PD-1 antibody), which exhibits a strong anti-tumor effect and thus is useful for the treatment of cancer.

Abstract: The object of the present invention is to provide a method for identifying a patient with malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, and agents for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, characterized by prescriptions based on those. The present invention can provide agents for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, characterized by prescriptions based on identifying a patient with a malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, by analyzing the evaluation items consisting of combinations such as the PD-1 expression intensity, the percentage of the number of PD-1 expressing cells and the like in Treg cells and CD8+ T cells in tumor tissue or blood.

Abstract: A medicament comprising a combination of a compound represented by formula (I), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these and an immune checkpoint inhibitor (such as an anti-PD-1 antibody), which exhibits a strong anti-tumor effect and thus is useful for the treatment of cancer.

Abstract: A personal information anonymization method is disclosed. Each of a plurality of data including personal information is classified into any one of a plurality of groups based on a degree of commonality of the personal information. An anonymization process, that standardizes the personal information of each of data belonging to each of the groups, is performed for each of the groups. A total number of the data belonging to each of the groups is calculated for each of the groups. The plurality of the groups are classified based on the total number of the sets of the data. A classification result is output.

Abstract: The present invention provides a cell culture vessel and a jig for fixing the cell culture vessel in position. More specifically, the cell culture vessel of the present invention is provided with a vessel portion having an annular sealed culture space when viewed from overhead and a port portion connecting the inner portion and outer portion of the culture space. The vessel portion is provided with a first vessel wall serving as the upper side during culturing and a second vessel wall serving as the lower side during culturing. Preferably at least the first vessel wall has flexibility.

Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

Abstract: A personal information anonymization method is disclosed. Each of a plurality of data including personal information is classified into any one of a plurality of groups based on a degree of commonality of the personal information. An anonymization process, that standardizes the personal information of each of data belonging to each of the groups, is performed for each of the groups. A total number of the data belonging to each of the groups is calculated for each of the groups. The plurality of the groups are classified based on the total number of the sets of the data. A classification result is output.

Abstract: A centrifugal separator separates liquid from solid and includes a hollow bowl and a screw conveyor, the solid discharged from one end of the bowl and the liquid discharged from plural liquid discharge ports at an opposite end of the bowl, the separator further includes a separated liquid jetting device which collects separated liquid that has overflowed the top of an overflow edge of a dam disposed on each discharge port. The separated liquid jetting device has a separated liquid retention chamber that temporarily retains the collected separated liquid inside thereof, a jet nozzle that is open in the direction opposite to the rotation direction of the bowl and that jets out the liquid located inside the separated liquid retention chamber to the outside and the separated liquid jetting device also has a release port formed above the jet nozzle.

Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

Abstract: Provided is a centrifugal separator equipped with a separated liquid jet nozzle, capable of reducing energy consumption on the rotational drive of a bowl, and capable of avoiding the problem of the solid contained in the raw liquid being discharged through a jet nozzle to a liquid recovery system, and the problem of the adverse effect being produced on the water content ratio in the discharged solid content when the treatment conditions are changed. A separated liquid jetting device 9, which collects the separated liquid that has overflowed the top of an overflow edge 7a of a dam 7, is attached to a front hub 8 at a position on radially outward of each of the liquid discharge ports 6.

Abstract: In a radiographic image capturing apparatus, an object to be examined is compressed and secured between a compression plate and an image capturing base, at a position off-center from a central position of the image capturing base near a subject in a direction along the subject. An opening is defined in the compression plate so as to confront the object to be examined in the off-center position. The radiation source irradiates the object to be examined as well as the opening with radiation from a central angle of the radiation source, which is aligned with a vertical axis of the image capturing base, and which passes through the central position from a predetermined angle that is angularly spaced from the central angle about the central position.

Abstract: The present invention provides a baglike container for centrifugation that is mounted in a centrifuge to thereby allow centrifugation of a dispersion liquid accommodated therein. The baglike container for centrifugation is less likely to tear or break as a result of centrifugation by disposing a container wall surface of the baglike container so as to apply centrifugal force perpendicular to the container wall surface.

Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

Abstract: In a radiographic image capturing apparatus, a biopsy region positional information calculator calculates a three-dimensional position of a biopsy region in an object to be examined based on two radiographic images which are acquired in a stereographic image capturing process, an irradiated field calculator calculates a new irradiated field covering the biopsy region based on the calculated three-dimensional position of the biopsy region and two angles at which a radiation source is disposed in the stereographic image capturing process, and a collimator controller controls a collimator to change the irradiated field of the radiation to the new irradiated field in a next stereographic image capturing process.

Abstract: A purpose of the present invention is to provide a method capable of more effectively prescribing an anti-human PD-1 antibody for anti-cancer therapy, a method for estimating or optimizing therapeutic efficacy thereof, and further an efficacy marker that can be used in methods thereof. The present invention enables selection of the cancer patient in whom the therapeutic efficacy of the anti-human PD-1 antibody can be expected in future, by measuring the change which is more than a certain level of several kinds of efficacy markers in blood, after administering the initial dose or doses of the anti-human PD-1 antibody compared to that prior to administering the initial dose, and provides a new prescription of the anti-human PD-1 antibody for anti-cancer therapy.

Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.